Which antidepressants have the lowest risk of hepatotoxicity and weight gain?

Bupropion and SSRIs (Escitalopram, Citalopram, Fluoxetine) Are Your Best Options

For antidepressants with the lowest combined risk of hepatotoxicity and weight gain, prescribe bupropion as first-line, or alternatively escitalopram, citalopram, or fluoxetine among the SSRIs.

Weight Gain Profile

Bupropion stands alone as the only commonly prescribed antidepressant consistently associated with weight loss or neutrality. In a large 2024 target trial emulation study of 183,118 patients, bupropion showed 0.22 kg less weight gain compared to sertraline at 6 months and was associated with a 15% reduced risk of gaining ≥5% of baseline weight 1. This makes it the clear winner for weight concerns.

Among SSRIs, if bupropion is not suitable:

• Fluoxetine showed similar weight change to sertraline (difference of only -0.07 kg) 1
• Citalopram had minimal additional weight gain (0.12 kg more than sertraline) 1
• Escitalopram had modest weight gain (0.41 kg more than sertraline) 1

Avoid these for weight concerns: Paroxetine and mirtazapine cause the highest weight gain among second-generation antidepressants 2, with paroxetine showing 0.37 kg additional gain and 10-15% higher risk of ≥5% weight gain 1. Duloxetine also carries increased weight gain risk (0.34 kg more than sertraline) 1.

Hepatotoxicity Profile

For liver safety, SSRIs are dramatically safer than other antidepressant classes. A large German surveillance study of 184,234 psychiatric inpatients found:

Lowest hepatotoxicity risk:

• Escitalopram: 0.01% incidence 3
• Citalopram: 0.02% incidence 3
• Fluoxetine: 0.02% incidence 3
• Overall SSRIs: 0.03% incidence 3

Higher hepatotoxicity risk to avoid:

• Mianserine: 0.36% 3
• Agomelatine: 0.33% 3
• Clomipramine: 0.23% 3
• Nefazodone: associated with increased hepatotoxicity risk 2

The research confirms that citalopram, escitalopram, paroxetine, and fluvoxamine have the least potential for hepatotoxicity 4. Notably, while 0.5-3% of patients on antidepressants may develop asymptomatic mild transaminase elevations, clinically significant liver injury occurs within the first 6 months of treatment 5, 4.

Clinical Algorithm

First-line choice: Bupropion

• Best weight profile (weight loss/neutral)
• Acceptable hepatotoxicity risk
• Caveat: Avoid in patients with seizure disorders or eating disorders

If bupropion contraindicated, choose based on priority:

If weight is the primary concern:

1. Fluoxetine (weight neutral, very low hepatotoxicity)
2. Citalopram (minimal weight gain, lowest hepatotoxicity)

If liver disease/risk is the primary concern:

1. Escitalopram (lowest hepatotoxicity, modest weight gain)
2. Citalopram (second-lowest hepatotoxicity, minimal weight gain)

Important Caveats

• Baseline monitoring: Check liver enzymes before starting any antidepressant, particularly in elderly patients or those on polypharmacy 4
• Surveillance window: Most liver injury occurs within 6 months of initiation; aminotransferase monitoring is the most useful detection tool 5, 4
• Genetic factors: CYP2C19 metabolizer status influences both efficacy and side effect risk 6, 7
• Long-term weight effects: Even SSRIs that appear weight-neutral initially may cause weight gain with prolonged use 7
• Sexual dysfunction trade-off: Bupropion has significantly lower rates of sexual adverse events compared to SSRIs 2, 5, which may improve adherence